![]() ![]() engages in the provision of advanced image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer. ![]() See which 3 stocks are most likely to make moves following their insider activities. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. The company has a Price to Book ratio of 6.49. ICAD’s market cap is currently $239.1M and has a P/E ratio of -31.00. See the top stocks recommended by analysts > ![]() ICAD has an analyst consensus of Moderate Buy, with a price target consensus of $21.00. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics. The company’s shares closed last Tuesday at $9.55, close to its 52-week low of $8.73.Īccording to, Turkaly is a 4-star analyst with an average return of 12.7% and a 52.9% success rate. In a report released today, David Turkaly from JMP Securities reiterated a Buy rating on iCAD ( ICAD – Research Report), with a price target of $18.00. JMP Securities Reiterates a Buy Rating on iCAD (ICAD) ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |